Skip to content
DataLookout
Menu

NCT05906511

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

StatusCompleted
PhaseEarly Phase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Aug 31, 2026 to Apr 13, 2026
    • Site details revised
    • Publications: details revised at 7 of 8 entries
  2. Minor Primary completion moved earlier from Jun 30, 2026 to Apr 13, 2026v9
  3. Minor Site contact updatedv8
  4. Notable Primary completion date: Aug 31, 2025 to Jun 30, 2026
    • Study completion date: Aug 31, 2025 to Aug 31, 2026
    • Study description shortened, about 5 words
    v7
  5. Notable Enrollment target: 30 to 20
    • Primary and study completion dates: Apr 30, 2025 to Aug 31, 2025
    • Study description expanded, about 1 word
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Jul 30, 2025 to Apr 30, 2025
    • Start date changed from estimate of Dec 1, 2023 to Oct 17, 2023
    • Site details revised
    v5
  2. Notable Start date: Oct 15, 2023 to Dec 1, 2023
    • Collaborators: 1 to 2
    v4
  3. Notable Enrollment target: 20 to 30
    • Start date: Sep 15, 2023 to Oct 15, 2023
    • Eligibility criteria expanded, about 133 words
    • Study description expanded, about 78 words
    v3
  4. Minor Primary completion date: Aug 2025 to Apr 30, 2025
    • Study completion date: Oct 2025 to Jul 30, 2025
    • Start date: Aug 2023 to Sep 15, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Peak concentration (Cmax)
Timeframe: Up to 8 hours
Time to attain Cmax concentration (Tmax)
Timeframe: Up to 8 hours
Area under the plasma concentration-time curve (AUC0-8h)
Timeframe: Up to 8 hours
Nociception
Timeframe: Up to 8 hours
Abuse Liability
Timeframe: Up to 8 hours

Arms and interventions

Dronabinol 5mgActive comparator

Dronabinol 5 mg

Dronabinol 10mgPlacebo comparator

Dronabinol 10 mg

Vaporized THC 2mgActive comparator

Vaporized THC 2mg

Vaporized THC 4mgActive comparator

Vaporized THC 4 mg

PlaceboPlacebo comparator

Masked oral placebo or vaporized saline

Drugs: Dronabinol 5 MG, Dronabinol 10 MG, 2mg Purified THC in an ethanolic solution, 4mg Purified THC in an ethanolic solution, Placebo

Sites

1 site in 1 country

  • VA Connecticut Healthcare SystemWest Haven, Connecticut, United States